AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01642433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 3x daily
Trial: NCT01889069
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
Trial: NCT01889069
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
Trial: NCT04621461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 5 days
Trial: NCT01426347
Drug: Placebo sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
Trial: NCT04276090
Drug: Hepatic artery infusion pump floxuridine and dexamethasone
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
Trial: NCT00130065
Drug: Sulfadoxine-pyrimethamine/folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03617835
Drug: R - Low dose of BI 655130
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
Trial: NCT03617835
Drug: T2 - Low dose of BI 655130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
Trial: NCT04324294
Drug: EUS enhanced with contrast to evaluate pancreas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
Trial: NCT01007968
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100mg twice daily
Trial: NCT01805817
Drug: YASMIN® (Drospirenone/Ethinyl Estradiol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral contraceptive pills
Trial: NCT03371823
Drug: Hypertensives
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
Trial: NCT00932646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Respimat once daily and placebo Foradil
Trial: NCT00391339
Drug: Bryophyllum p.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04170296
Drug: EN3835
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase Clostridium Histolyticum (CCH)
Trial: NCT02498379
Drug: Cu[64]-25%CANF-Comb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
Trial: NCT04733196
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Trial: NCT03016793
Drug: β- tricalcium phosphate
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
Trial: NCT03016793
Drug: β- tricalcium phosphate alone
RxNorm normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
Trial: NCT01267669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency EVL plus placebo infusion for 5 days
Trial: NCT02538315
Drug: [18F]FDOPA PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
Trial: NCT02201901
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg tablets administered orally once daily
Trial: NCT00372853
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
Trial: NCT00372853
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 administered at a dose of 37.5mg/day every day.
Trial: NCT00372853
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
Trial: NCT03210649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
Trial: NCT00814515
Drug: NOVA22007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT01288781
Drug: Lactose monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
Trial: NCT00895726
Drug: APD209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets twice per day for 56 days
Trial: NCT01186328
Drug: EZN-3042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
Trial: NCT01186328
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
Trial: NCT00113815
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02779348
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone tablets 200 mg
Trial: NCT02414009
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
Trial: NCT02414009
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
Trial: NCT02414009
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
Trial: NCT00321685
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00321685
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00321685
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01186328
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg
Trial: NCT01186328
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg
Trial: NCT04854538
Drug: Ekmasonid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 extended release tablet contains 9 mg Budesonide
Trial: NCT01267825
Drug: Standard medical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen + Oxycodone/ Acetaminophen
Trial: NCT00674635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01486615
Drug: meloset (melatonin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin tablet 1-2 hour prior surgery
Trial: NCT01486615
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar looking placebo tablet
Trial: NCT02219698
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01382940
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 to 25 mg/week (oral or parenteral)
Trial: NCT01382940
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
Trial: NCT00000469
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00566813
Drug: Islet Cell Transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
Trial: NCT00566813
Drug: Islet Cell Transplant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
Trial: NCT04303507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04249336
Drug: Fluoro-Calcium-Phospho-Silicate based dentifrices
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-Active glass based formulation
Trial: NCT04259359
Drug: Insect Venom
RxNorm normalized name: insect venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
Trial: NCT00563589
Drug: mycophenolate mofetil, methotrexate, cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00563589
Drug: Methotrexate and cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00781742
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV once per dosing day, multiple times during the treatment period
Trial: NCT00781742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline IV once per dosing day multiple times during the treatment period
Trial: NCT02127320
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02127320
Drug: Rosuvastatin 20mg + Ezetimibe 10mg
RxNorm normalized name: ezetimibe / rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00590564
Drug: Sho-saiko-to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
Trial: NCT00656201
Drug: Crinone 8% Vaginal Gel
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
Trial: NCT03430544
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
Trial: NCT03102489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray
Trial: NCT02356705
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal saline given as placebo
Trial: NCT02453061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil orally administered at 1g/kg/day
Trial: NCT01033292
Drug: BSI-201
RxNorm normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 5.6 mg/kg
Trial: NCT02357888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oromucosal - Single dose
Trial: NCT02557126
Drug: URC102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02557126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162708
Drug: CDDP, 5 Fu
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01475461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-dummy placebo tablets administered once-daily for 84-days
Trial: NCT02643719
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
Trial: NCT04197076
Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
Trial: NCT04197076
Drug: investigator decided
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT02095990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027521
Drug: electroporation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01694810
Drug: 2% NVN1000 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% NVN1000 Topical Gel once daily for 4 weeks
Trial: NCT01694810
Drug: 4% NVN1000 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% NVN1000 4% Topical Gel applied once daily 4 weeks
Trial: NCT01694810
Drug: 8% NVN1000 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% NVN1000 Topical Gel applied once daily for 4 weeks
Trial: NCT00807521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dexamethasone
Trial: NCT00082537
Drug: Comparator: AmBisome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 28-90 days
Trial: NCT01951768
Drug: Garamycin Sponge (Gentamicin-Collagen sponge)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Trial: NCT01951768
Drug: Systemic Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h
Trial: NCT00462722
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg with each exercise session (up to 5 days per week) for 9 months
Trial: NCT00462722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: with each exercise session (up to 5 days per week) for 9 months
Trial: NCT02670538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule one per day orally.
Trial: NCT02450812
Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to Summary of Product Characteristics
Trial: NCT03603639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive E2730-matched placebo capsule, orally.
Trial: NCT01896180
Drug: ALZ-1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ-1101 Ophthalmic Solution
Trial: NCT02934204
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00607672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02100540
Drug: II RDC 0.3mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: II RDC 0.3mg capsule
Trial: NCT02100540
Drug: III RDC 0.6mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: III RDC 0.6mg capsule
Trial: NCT03103022
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
Trial: NCT03103022
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
Trial: NCT02057575
Drug: PG324 Ophthalmic Solution 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Trial: NCT02057575
Drug: PG324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Trial: NCT02839785
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
Trial: NCT02839785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.